Clinical Trials Browser

Sarcoma, Kaposi

NCT01785810 2021-01-11

Phase II Maraviroc for GVHD Prevention

Phase 2 Completed

37 enrolled 17 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Phase 2 Completed

279 enrolled 28 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Phase 2 Unknown

40 enrolled

LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Clinical Trials

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Phase II Maraviroc for GVHD Prevention

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation